Merus rises after US FDA approves therapy to treat lung, pancreatic cancers

Merus NV

05/12/2024 12:34

** U.S.-listed shares of Netherlands-based Merus  2GH.F 
 MRUS.O  rise 2.3% to $46.53 premarket
    ** Late on Wednesday, U.S. FDA approved the drugmaker's
therapy that targets a particular gene, offering a treatment
option for patients with hard-to-treat type of lung and
pancreatic cancers
    ** Bizengri, MRUS' first commercial product, is expected to
be available to patients in the coming weeks - co
    ** Up to last close, stock up 65.4% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))